Acumen presents results from its Phase 2 ALTITUDE-AD study of sabirnetug

Acumen (ABOS) Pharmaceuticals announced results showing that implementing a blood-based pTau217 screening assay reduced Acumen’s overall clinical trial screening costs by approximately 40% in its Phase 2 ALTITUDE-AD study of sabirnetug in early Alzheimer’s disease in the U.S. and Canada. Additionally, a nonclinical study revealed sabirnetug achieved the highest selectivity for AbetaOs over Abeta monomers relative to recombinant lecanemab and aducanumab. The results are being presented at the Alzheimer’s Association International Conference, AAIC, taking place July 27-31, 2025, in Toronto and online. Acumen reported operational innovations in its ALTITUDE-AD Phase 2 clinical trial where researchers implemented an innovative two-step screening process using plasma pTau217 biomarker assay testing that yielded significant clinical trial screening and cost efficiencies. The approach reduced total screening costs by approximately 40% across U.S. and Canadian sites.